ReviewGut and liver2021
Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Review in Gut and liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials.International journal of immunopathology and pharmacologyPooled it
- Vonoprazan-amoxicillin dual therapy forSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy forPathogens (Basel, Switzerland) · 2025Trial
- Trial
- Review
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- Clinical Effectiveness and Application Strategies of Bismuth Quadruple Therapy: Analysis of the European Helicobacter Pylori Registry (Hp-EuReg).The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- The efficacy and safety of Vonoprazan and Tegoprazan inTherapeutic advances in gastroenterology · 2025Article
- Review
- Antibiotic Susceptibility-Guided Concomitant Therapy Regimen with Vonoprazan, High-Dose Amoxicillin, Clarithromycin, and Metronidazole forMicroorganisms · 2024Article
- Observational
- Single-Arm, Prospective, Interventional Study ofJournal of clinical medicine · 2024Article
- Comparison of metronidazoleJGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Article
- Antibiotic Resistance ofJournal of Korean medical science · 2024Review
- OptimizingGut and liver · 2023Review
- Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-ResistantJournal of clinical medicine · 2023Article
- Proton pump inhibitors display anti-tumour potential in glioma.Cell proliferation · 2023Review
- Vonoprazan and high-dose amoxicillin dual therapy forJGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics andJournal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been approved and used for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.